Wednesday’s Highlights at Noon: Rosetta Genomics Ltd (ROSG), Yingli (YGE), MannKind (MNKD), Microvision (MVIS), Sangamo Biosciences (SGMO)

By Carrie Williams

So far Wednesday, September 5, NASDAQ is down -2.23% and the S&P is down -0.06%. Here are this morning’s most active stocks: Rosetta Genomics Ltd (NASDAQ:ROSG), Yingli (NYSE:YGE), MannKind (NASDAQ:MNKD), Microvision (NASDAQ:MVIS) and Sangamo Biosciences (NASDAQ:SGMO).

Rosetta Genomics Ltd is up 660% in midday trading to $0.02. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Yingli is up 20.4% in midday trading to $0.30. Shares opened today at $0.25. The company has a 52-week low of $0.20 and a 52-week high of $0.00.

MannKind is up 15.98% in midday trading to $2.84. Shares opened today at $2.45. The company has a 52-week low of $0.98 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.00, marking a 63.27% potential upside from current levels. In a report released today, H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on MNKD, with a price target of $4, which implies an upside of 63% from current levels. Separately, on June 15, Maxim Group’s Jason McCarthy maintained a Hold rating on the stock .

See today’s analyst top recommended stocks >>

Microvision is up 13.25% in midday trading to $1.18. Shares opened today at $1.04. The company has a 52-week low of $0.89 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $4.00, marking a 284.62% potential upside from current levels. In a report issued on August 7, H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on MVIS, with a price target of $3.50, which implies an upside of 237% from current levels. In the last 30 days, insiders purchased $24K worth of MVIS shares.

See today’s analyst top recommended stocks >>

Sangamo Biosciences is down -11.16% in midday trading to $14.93. Shares opened today at $16.80. The company has a 52-week low of $11.30 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $19.00, marking a 13.10% potential upside from current levels. In a report issued on August 9, Jefferies Co. analyst Maury Raycroft maintained a Buy rating on SGMO, with a price target of $28, which represents a potential upside of 67% from where the stock is currently trading. Separately, on the same day, Wedbush’s Liana Moussatos reiterated a Hold rating on the stock and has a price target of $10.

Trending Stocks Based on Insider Activity >>